Detalles de la búsqueda
1.
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Lancet Oncol
; 16(5): 583-94, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25892145
2.
Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab.
J Immunother Cancer
; 11(5)2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37217243
3.
Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors - A phase I trial.
Front Immunol
; 13: 1023023, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36330525
4.
The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification.
Clin Cancer Res
; 27(3): 689-703, 2021 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33122346
5.
Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study.
Cancers (Basel)
; 13(4)2021 Feb 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-33671555
6.
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
Nat Med
; 27(12): 2212-2223, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34887574
7.
Rectal cancer survival in the Nordic countries and Scotland.
Int J Cancer
; 125(10): 2406-12, 2009 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19588486
8.
In vivo antitumor efficacy of interleukin-21 in combination with chemotherapeutics.
Cytokine
; 48(3): 231-8, 2009 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-19709902
9.
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials.
Lung Cancer
; 133: 10-19, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31200814
10.
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.
JAMA Oncol
; 5(8): 1170-1180, 2019 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31194247
11.
Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung.
Onco Targets Ther
; 11: 8565-8573, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30573970
12.
Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy.
Clin Lung Cancer
; 19(1): 74-83.e11, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28729180
13.
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.
JAMA Oncol
; 4(9): 1189-1197, 2018 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29902295
14.
Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.
Lung Cancer
; 109: 101-108, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28577938
15.
Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
Nat Med
; 28(4): 871, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35260843
16.
Increased thymidylate synthase mRNA concentration in blood leukocytes following an experimental stressor.
Psychother Psychosom
; 71(2): 97-103, 2002.
Artículo
en Inglés
| MEDLINE | ID: mdl-11844946
Resultados
1 -
16
de 16
1
Próxima >
>>